Outcomes of Patients with Metastatic Clear-cell Renal Cell Carcinoma Treated with Second-Line VEGFR-TKI after First-Line Immune Checkpoint Inhibitors

BACKGROUND: Immune checkpoint inhibitors (ICI) are being increasingly utilized in the front-line (1L) setting of metastatic clear-cell renal cell carcinoma (mccRCC). Limited data exist on responses and survival on second-line (2L) VEGFR-TKI therapy after 1L ICI therapy. PATIENTS AND METHODS: This is...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Eur J Cancer
Главные авторы: Shah, AY, Kotecha, RR, Lemke, EA, Chandramohan, A, Chaim, JL, Msaouel, P, Xiao, L, Gao, J, Campbell, MT, Zurita, AJ, Wang, J, Corn, PG, Jonasch, E, Motzer, RJ, Sharma, P, Voss, MH, Tannir, NM
Формат: Artigo
Язык:Inglês
Опубликовано: 2019
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7537491/
https://ncbi.nlm.nih.gov/pubmed/31075726
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejca.2019.04.003
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы